Race Oncology Ltd. (AU:RAC) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Race Oncology Ltd is set to hold its Annual General Meeting, where key updates on its lead asset, bisantrene, will be shared with shareholders. The company focuses on advancing bisantrene for cancer treatment, highlighting its unique safety profile and potential to meet unmet needs in oncology. Race Oncology is also seeking strategic partnerships to enhance global access to this promising asset.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.